{Reference Type}: Journal Article
{Title}: Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma.
{Author}: Zhao L;Shen Z;Kroemer G;Kepp O;
{Journal}: Oncoimmunology
{Volume}: 13
{Issue}: 1
{Year}: 2024
暂无{DOI}: 10.1080/2162402X.2024.2360275
{Abstract}: Recently, it was revealed that the high-risk, poor-prognosis downregulation of GABA type A receptor-associated protein (GABARAP) causes a defect in both autophagy and surface exposure of calreticulin (CALR) in multiple myeloma (MM) cells responding to bortezomib. Hence, GABARAP-defective MM cells fail to undergo immunogenic cell death.